Form 4: Cogent Biosciences Director Acquires Stock Options in Lieu of Cash Compensation

Director Karen Jean Ferrante acquired 2,785 stock options in Cogent Biosciences in lieu of cash compensation, according to a recent SEC filing.

Summary

• Karen Jean Ferrante, a director at Cogent Biosciences, Inc., acquired 2,785 stock options on January 1, 2025.
• The options were granted in lieu of cash compensation for services as a director, as per the Issuer's non-employee director compensation plan.
• The exercise price of the options is $7.80.
• The options are exercisable from January 1, 2025, and expire on January 1, 2035.
• Following the transaction, Ferrante directly owns 2,785 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. A director taking equity in lieu of cash suggests confidence in the company's future, but it's a routine transaction.

Positives

• A director taking equity in lieu of cash compensation can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This type of equity compensation is common for directors of publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Director compensation packages often include a mix of cash and equity.
• The specific terms of the option grant (exercise price, vesting schedule, expiration date) are typical for director compensation plans.
• Comparing the Black-Scholes value of these options to similar grants at comparable biotech companies would provide further context.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with theirs.

Key Dates